Market News / Story
FTH — Multi-node PAM inhibition advances toward endometrial and breast proof-of-concept readouts
Quartr ·
Quartr reports: PIKTOR’s oral multi-node PAM strategy targets broad pathway coverage, with endometrial topline expected by year-end 2026 and breast interim data in 2H 2027. Clinical evidence is promising but remains investigational and cross-trial comparisons are limited. Original document: Faeth Therapeutics, Inc. [FTH] Slides Release — Oct. 6 2026 This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.